<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795650</url>
  </required_header>
  <id_info>
    <org_study_id>2015-004860-12</org_study_id>
    <nct_id>NCT02795650</nct_id>
  </id_info>
  <brief_title>Personalised Therapy for Metastatic ADPC Determined by Genetic Testing and Avatar Model Generation</brief_title>
  <acronym>AVATAR</acronym>
  <official_title>Personalised Therapy for Patients With Metastatic Adenocarcinoma of the Pancreas Determined by Genetic Testing and Avatar Model Generation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario de Fuenlabrada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario de Fuenlabrada</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open label, randomised phase II clinical trial for patients with&#xD;
      metastatic adenocarcinoma of the pancreas. Patients randomised to the experimental arm will&#xD;
      undergone tumoral biopsy before starting first line of treatment and will be administered&#xD;
      personalised therapy as second or third line.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open label, randomised phase II clinical trial for patients with&#xD;
      metastatic adenocarcinoma of the pancreas.&#xD;
&#xD;
      Patients with metastatic disease will be randomised to the experimental or control arms.&#xD;
      Those in the experimental arm will undergone a tumoral biopsy in order to perform exome&#xD;
      sequencing, bioinformatic report, and avatar mouse models for drug testing. This information&#xD;
      will allow the expertise panel to elaborate a treatment recommendation as second or third&#xD;
      lines of treatment. Patients in the control arm will receive treatment as per investigator´s&#xD;
      judge. The main objective of the trial is to determine whether personalised treatments&#xD;
      achieve improved 1-year overall survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year overall survival</measure>
    <time_frame>1-year overall survival</time_frame>
    <description>Efficacy. 1-year overall survival</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Personalised treatment will be chosen for patients based on the results of tumor sequencing, bioinformatics and avatar model drug testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigators are allowed to chose the best option of standard treatment for patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Personalised treatment</intervention_name>
    <description>Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment chosen per investigator´s judge</intervention_name>
    <description>Investigators are allowed to chose what they consider the best standard treatment option for their patients.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of adenocarcinoma of the pancreas.&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Age ≥ 18 years old.&#xD;
&#xD;
          -  Willingness of male and female subjects, who are not surgically sterile or&#xD;
             postmenopausal, to use reliable methods of birth control (oral contraceptives,&#xD;
             intrauterine devices, or barrier methods used with a spermicide) for the duration of&#xD;
             the study.&#xD;
&#xD;
          -  One or more sites of metastasis with one of the susceptible of biopsy.&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No prior treatment with radiotherapy, surgery, chemotherapy or investigational&#xD;
             treatment for the metastatic disease or no more than the three cycles of first line&#xD;
             chemotherapy. Palliative radiotherapy for bone metastasis is allowed. Adjuvant or&#xD;
             neoadjuvant radiotherapy or chemotherapy are allowed if they finished more that 6&#xD;
             months ago and the patient has no remaining toxicities.&#xD;
&#xD;
          -  Bone marrow function as follows, no more than 14 days prior to randomisation:&#xD;
&#xD;
        ANC &gt; 1,500 cells/mm3 Platelets &gt; 100,000 cells/mm3 Hemoglobin ≥9 g/dl&#xD;
&#xD;
          -  Adequate liver, renal and bone marrow functions.&#xD;
&#xD;
               -  AST (SGOT), ALT (SGPT) ≤ 2.5 × ULN and ≤ 5 x ULN if liver metastases.&#xD;
&#xD;
               -  Bilirubin ≤ 1,5 x ULN&#xD;
&#xD;
               -  Albumin total ≥ 0,75 ULN&#xD;
&#xD;
               -  Creatinine ≤ 1,5 x ULN&#xD;
&#xD;
          -  Ability to sign informed consent&#xD;
&#xD;
          -  Patients will be allowed to be randomised just once.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Brain metastases, unless they have been previously treated and stable for 3 months at&#xD;
             least (defined as no oedema, no need of steroids and stable disease in two CT scans&#xD;
             separated by a minimum of 4 weeks).&#xD;
&#xD;
          -  Locally advanced disease.&#xD;
&#xD;
          -  Malignancies other than pancreatic cancer diagnosed within 5 years prior to&#xD;
             randomization, except for adequately treated carcinoma in situ or basal or squamous&#xD;
             cell skin cancer.&#xD;
&#xD;
          -  Bacterial, viral or fungal active infection that require systemic treatment.&#xD;
&#xD;
          -  Any contraindication for tumor biopsy.&#xD;
&#xD;
          -  Past or present HIV or hepatitis B or C infection.&#xD;
&#xD;
          -  Severe medical problems affecting organs or psychiatric illnesses that could interfere&#xD;
             with the safety of the patient in the trial.&#xD;
&#xD;
          -  Pregnancy or breastfeeding women.&#xD;
&#xD;
          -  Patient will need to be informed and agree to undergo tumoral biopsy in the&#xD;
             experimental arm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Hidalgo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 1, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

